Baird Initiates Coverage on Abbott Laboratories (ABT) with Outperform Rating
On June 30, Baird initiated coverage on Abbott Laboratories (NYSE:ABT), assigning an 'Outperform' rating and a price target of $121. The firm anticipates steady revenue and earnings growth driven by the company's medical device segment and new product opportunities.
Tickers: $ABT